Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

References

• Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013;382(9893):720-31
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239-46
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6
   PubMed Web of Science ®Google Scholar
• Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46(10):1773-80
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703
   PubMed Web of Science ®Google Scholar
• Crino L, Kim D, Riely GJ, et al. Initial phase Ii results with crizotinib in, profile Aa-PN-SCLCN. AMA 2011;29:7514
   Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13(10):1011-19
   PubMed Web of Science ®Google Scholar
• Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105(9):595-605
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
   PubMed Web of Science ®Google Scholar
• Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17(5):1169-80
   PubMed Web of Science ®Google Scholar
• Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30(4):433-40
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3(75):75ra26
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305(5687):1163-7
   PubMed Web of Science ®Google Scholar
• Landi L, Capuzzo F. Irreversible EGFR-TKIs: dreaming perfection. Transl Lung Cancer Res 2013;2(1):40-9
   PubMedGoogle Scholar
• Querings S, Altmuller J, Ansen S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011;6(5):e19601
   Web of Science ®Google Scholar
• Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in Erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17(5):1160-8
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359(4):366-77
   PubMed Web of Science ®Google Scholar
• Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009;15(10):3484-94
   PubMed Web of Science ®Google Scholar
• Rosell R, Karachaliou N. Lung cancer: maintenance therapy and precision medicine in NSCLC. Nat Rev Clin Oncol 2013;10(10):549-50
   PubMed Web of Science ®Google Scholar
• Rosell R, Molina-Vila MA, Drozdowskyj A, et al. Impact of EGFR T790M mutations and BIM mRNA expression on progression-free survival (PFS) and overall survival (OS) in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Poster Session 2 Prognostic and Predictive Biomarkers P2.06-012 IASLC; 2013
   Google Scholar
• Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012;83(3):407-21
   PubMed Web of Science ®Google Scholar
• Garuti L, Roberti M, Bottegoni G. Irreversible protein kinase inhibitors. Curr Med Chem 2011;18(20):2981-94
   PubMed Web of Science ®Google Scholar
• Kim SM, Kwon OJ, Hong YK, et al. Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 2012;11(10):2254-64
   PubMed Web of Science ®Google Scholar
• Yu HA, Pao W. Targeted therapies: afatinib-new therapy option for EGFR-mutant lung cancer. Nat Rev Clin Oncol 2013;10(10):551-2
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31(27):3327-34
   PubMed Web of Science ®Google Scholar
• Carpenter RL, Lo HW. Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer. J Thorac Dis 2012;4(6):639-42
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 2010;9(6):1647-56
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 2013;12(5):589-97
   PubMed Web of Science ®Google Scholar
• Yamada T, Takeuchi S, Fujita N, et al. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene 2013;32(37):4427-35
   PubMed Web of Science ®Google Scholar
• Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013;3(12):1404-15
   PubMed Web of Science ®Google Scholar
• Berardi R, Santoni M, Morgese F, et al. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Oncoi Targets Ther 2013;6:563-76
   PubMed Web of Science ®Google Scholar
• Soria J-C. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). IASLC 2013 O03.06: NSCLC – targeted therapies I oral abstract session: Medical Oncology; 2013
   Google Scholar
• [No authors listed] Targeting resistance in lung cancer. Cancer Discov 2013;3(12):OF9
   Web of Science ®Google Scholar
• Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4(10):1669-79; discussion 1680
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Rothenberg SM, Hata AN, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 2013;5(196):196ra198
   Web of Science ®Google Scholar
• Han D, Li SJ, Zhu YT, et al. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev 2013;14(7):4033-9
   PubMedGoogle Scholar
• Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 2013;32(33):3846-56
   PubMed Web of Science ®Google Scholar
• Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011;471(7339):523-6
   PubMed Web of Science ®Google Scholar
• Sangodkar J, Dhawan NS, Melville H, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 2012;122(7):2637-51
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhou J, Giobbie-Hurder A, et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19(3):598-609
   PubMed Web of Science ®Google Scholar
• Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013;13(11):772-87
   PubMed Web of Science ®Google Scholar
• Bellacasa R, Karachaliou N, Estrada-Tejedor R, et al. Alk and Ros1 as a joint target for the treatment of lung cancer: a review. Transal Lung Cancer Res 2013;2:2
   Google Scholar
• Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011;47(1):R11-23
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Rosell R. Optimal detection of ALK rearranged lung adenocarcinomas. J Thorac Oncol 2013;8(3):255-6
   PubMed Web of Science ®Google Scholar
• Chihara D, Suzuki R. More on crizotinib. N Engl J Med 2011;364(8):776-7; author reply 778
   PubMedGoogle Scholar
• Tuononen K, Sarhadi VK, Wirtanen A, et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. BioMed Res Int 2013;2013:757490
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18(5):1472-82
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4(120):120ra117
   Web of Science ®Google Scholar
• Shaw AT, Mehra R, Kim D-W, et al. Clinical activity of the Alk inhibitor Ldk378 in advanced, Alk-positive Nsclc. J Clin Oncol 2013;31(Suppl):Abstract 8010
   Google Scholar
• Camidge DR, Bazhenova L, Salgia R, et al. First-in-human dose-finding study of the Alk/Egfr inhibitor Ap26113 in patients with advanced malignancies: updated results. J Clin Oncol 2013;31(Suppl):Abstract 8031
   Google Scholar
• Gadgeel S, Ou S, Chiappori A, et al. A Phase I dose escalation study of a new Alk inhibitor, Ch542480202, in Alk+ non-small cell lung cancer patients who have failed crizotinib [abstract O16.06]. Presented at the 15th World Conference on Lung Cancer; 29 October 2013; Sydney Australia
   Google Scholar
• Ou SH, Gadgeel S, Chiappori AA, et al. Consistent therapeutic efficacy of Ch5424802/Ro5424802 in brain metastases among crizotinib-refractory Alk-positive non-small cell lung cancer patients in an ongoing Phase I/Ii study [abstract O16.07]. Presented at the 15th World Conference on Lung Cancer; 29 October 2013; Sydney, Australia
   Google Scholar
• Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013;3(4):430-43
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okabe T, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 2012;18(22):6219-26
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Nishio K, Janne PA. Nakagawa K. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 2011;17(8):2140-8
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Takezawa K, et al. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. Br J Cancer 2012;106(4):763-7
   PubMed Web of Science ®Google Scholar